Swedencare AB (publ) (SECARE.ST)
SEK 36.45
(1.11%)
SEK 36.45
(1.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.42 Billion SEK | -14.45% |
| 2022 | 1.66 Billion SEK | 183.77% |
| 2021 | 585.44 Million SEK | 655.59% |
| 2020 | -105.37 Million SEK | -149.51% |
| 2019 | -42.23 Million SEK | -120.64% |
| 2018 | -19.14 Million SEK | -170.47% |
| 2017 | -7.07 Million SEK | -258.7% |
| 2016 | 4.45 Million SEK | 165.37% |
| 2015 | -6.82 Million SEK | -142.17% |
| 2014 | -2.81 Million SEK | -563.28% |
| 2013 | -424.7 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.41 Billion SEK | -0.15% |
| 2024 Q3 | 1.34 Billion SEK | -6.13% |
| 2024 Q2 | 1.43 Billion SEK | 0.89% |
| 2023 Q1 | 1.66 Billion SEK | 0.16% |
| 2023 Q4 | 1.42 Billion SEK | -6.51% |
| 2023 FY | 1.42 Billion SEK | -14.45% |
| 2023 Q3 | 1.52 Billion SEK | -8.0% |
| 2023 Q2 | 1.65 Billion SEK | -0.69% |
| 2022 Q1 | 1.32 Billion SEK | 125.76% |
| 2022 Q3 | 2.55 Billion SEK | 85.16% |
| 2022 FY | 1.66 Billion SEK | 183.77% |
| 2022 Q2 | 1.38 Billion SEK | 4.56% |
| 2022 Q4 | 1.66 Billion SEK | -35.08% |
| 2021 Q4 | 585.44 Million SEK | 21.99% |
| 2021 FY | 585.44 Million SEK | 655.59% |
| 2021 Q3 | 479.93 Million SEK | 146.55% |
| 2021 Q2 | -1.03 Billion SEK | -5502.38% |
| 2021 Q1 | -18.4 Million SEK | 82.54% |
| 2020 Q3 | -361.78 Million SEK | -107.87% |
| 2020 FY | -105.37 Million SEK | -149.51% |
| 2020 Q2 | -174.04 Million SEK | -312.77% |
| 2020 Q1 | -42.16 Million SEK | 0.16% |
| 2020 Q4 | -105.37 Million SEK | 70.87% |
| 2019 Q3 | -37.67 Million SEK | -16.55% |
| 2019 Q2 | -32.32 Million SEK | -37.32% |
| 2019 FY | -42.23 Million SEK | -120.64% |
| 2019 Q1 | -23.54 Million SEK | -22.99% |
| 2019 Q4 | -42.23 Million SEK | -12.1% |
| 2018 Q4 | -19.14 Million SEK | -30.59% |
| 2018 FY | -19.14 Million SEK | -170.47% |
| 2018 Q3 | -14.65 Million SEK | -46.98% |
| 2018 Q2 | -9.97 Million SEK | -77.31% |
| 2018 Q1 | -5.62 Million SEK | 20.53% |
| 2017 FY | -7.07 Million SEK | -258.7% |
| 2017 Q2 | 162 Thousand SEK | -95.82% |
| 2017 Q3 | -1.01 Million SEK | -728.4% |
| 2017 Q4 | -7.07 Million SEK | -595.19% |
| 2017 Q1 | 3.87 Million SEK | -13.11% |
| 2016 Q1 | 6.6 Million SEK | 196.83% |
| 2016 Q4 | 4.45 Million SEK | 116.56% |
| 2016 Q3 | -26.92 Million SEK | 2.36% |
| 2016 Q2 | -27.57 Million SEK | -517.39% |
| 2016 FY | 4.45 Million SEK | 165.37% |
| 2015 FY | -6.82 Million SEK | -142.17% |
| 2015 Q4 | -6.82 Million SEK | 0.0% |
| 2015 Q1 | 2.81 Million SEK | 0.0% |
| 2014 FY | -2.81 Million SEK | -563.28% |
| 2013 FY | -424.7 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 7485.679% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 4984.192% |
| BioGaia AB (publ) | -1.53 Billion SEK | 192.569% |
| Enzymatica AB (publ) | 17.73 Million SEK | -7913.193% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | 24960.941% |
| Gabather AB (publ) | -1.11 Million SEK | 127570.852% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | -7936.754% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 2646.311% |
| Nanexa AB (publ) | -61.13 Million SEK | 2424.817% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 9387.721% |
| ODI Pharma AB | -2.63 Million SEK | 53979.858% |
| Orexo AB (publ) | 302.8 Million SEK | -369.386% |
| Probi AB (publ) | -275.85 Million SEK | 615.238% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 92.741% |
| Toleranzia AB | -17.45 Million SEK | 8243.119% |
| Vivesto AB | -1.29 Million SEK | 109514.935% |